Abstract
Several observational studies showed an association between low circulating levels of 25-hydroxy-vitamin D (25-OH-VitD) and an increase of inflammatory activity in Multiple Sclerosis (MS). The aim of our study is to evaluate disease activity and CD19 kinetic in Ocrelizumab-treated MS patients, and their associations with 25-OH-VitD levels.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
